BRAF and neoplasm: Currently, the National Comprehensive Cancer Network (NCCN) recommends germline and somatic tumor testing for all patients with epithelial ovarian cancer at the time of diagnosis and recommends that somatic testing includes the evaluation of, at a minimum: BRCA1/2 mutations, homologous recombination deficiency (HRD) status, microsatellite instability (MSI), tumor mutation burden (TMB), and NTRK, BRAF, FRα, and RET, as mutations in these genes have implications for therapies [5].